ReviewGastroenterology2015
Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases.
Review in Gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 67 citations in OpenAlex.
- Metabolome and microbiome alterations related to short-term feeding of a micronutrient-fortified, high-quality legume protein-based food product to stunted school age children: A randomized controlled pilot trial.Clinical nutrition (Edinburgh, Scotland) · 2020Trial
- Regulatory T cells as a potential treatment for autoimmune inflammatory rheumatic and musculoskeletal diseases.Clinical rheumatology · 2026Review
- Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Identification and Validation of Biomarkers to Predict Early Diagnosis of Inflammatory Bowel Disease and Its Progression to Colorectal Cancer.Biochemical genetics · 2025Article
- Human intestinal microbiome: Role in health and disease.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024Review
- Proton pump Inhibitors and Risk of Enteric Infection in Inflammatory Bowel Disease: A Self-controlled Case Series.Inflammatory bowel diseases · 2024Article
- Gut-brain axis and neurodegeneration: mechanisms and therapeutic potentials.Frontiers in neuroscience · 2024Review
- Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies.World journal of gastroenterology · 2023Review
- Genome-wide DNA methylation profiling in differentiating Crohn's disease from intestinal tuberculosis.Genes & genomics · 2022Article
- The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD).Inflammatory bowel diseases · 2022Article
- Article
- Enterogenous Microbiotic Markers in the Differential Diagnosis of Crohn's Disease and Intestinal Tuberculosis.Frontiers in immunology · 2022Article
- Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases.Frontiers in pharmacology · 2022Review
- Temporal variability in quantitative human gut microbiome profiles and implications for clinical research.Nature communications · 2021Article
- Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases.International journal of molecular sciences · 2021Review
- Gut dysbiosis and clinical phases of pancolitis in patients with ulcerative colitis.MicrobiologyOpen · 2021Article
- The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review.Therapeutic advances in gastroenterology · 2021Review
- Diversity Scaling Analysis of Chinese Gut Microbiomes Across Ethnicities and Lifestyles.Frontiers in microbiology · 2021Article
- Nonclostridium difficile enteric infection and the risk of developing inflammatory bowel disease: A systematic review and meta-analysis.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2020Article
- Serum Biomarkers for Inflammatory Bowel Disease.Frontiers in medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The microbiome plays multifaceted roles in the pathogenesis of inflammatory bowel diseases (IBD). Accordingly, the clinical challenge of patient heterogeneity in disease phenotype and response to treatment should in part be addressed by biomarkers that detect the host response to microbiota, and the levels of microbial taxa and products eliciting the host response in susceptible individuals. Molecular analysis has revealed much evidence for microbial taxonomic membership and microbial products in association with IBD, but their utility as clinical biomarkers is still in its infancy. A rich area of progress has been the development and validation of host serologic microbial biomarkers, which have achieved a distinctive position in the diagnosis and prognosis in IBD, and as a template for defining other categories of microbial biomarkers in disease state and phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.